NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
Portfolio Pulse from
Nanobiotix has completed a Phase 1 study of its nanoparticle-based therapy, NBTXR3 (JNJ-1900), for pancreatic cancer. The study was conducted by MD Anderson Cancer Center and focused on dose escalation and expansion for locally advanced and borderline resectable pancreatic cancer.
December 09, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nanobiotix has completed a Phase 1 study of NBTXR3 for pancreatic cancer, marking progress in its nanoparticle-based therapies. This could lead to further clinical trials and potential market approval.
The completion of a Phase 1 study is a critical milestone for biotech companies, indicating progress in clinical development. This could lead to further trials and potential market approval, positively impacting Nanobiotix's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90